Megaplex

Megestrol acetate, the active ingredient in Megaplex, is a progestogen presented as a tablet for oral use. It is employed to stimulate appetite in cachexia associated with cancer or AIDS and as hormonal therapy for hormone‑responsive breast cancer and endometrial cancer. GNH USA supplies Megaplex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Megestrol acetate acts on hormonal pathways that influence metabolism and tumor growth. - Cachexia associated with cancer or AIDS: improves appetite and promotes weight gain. - Hormone‑responsive breast cancer: provides antineoplastic effect through anti‑estrogenic activity. - Endometrial cancer: used as hormonal therapy to inhibit tumor proliferation.

Megaplex may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Edema or fluid retention - Weight gain - Hypertension - Fatigue - Mild abdominal discomfort

Serious or Rare Side Effects: - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Adrenal suppression or Cushing‑like syndrome - Severe allergic reactions (anaphylaxis, skin rash) - Hepatic dysfunction (elevated enzymes, jaundice) - Hyperglycemia or worsening diabetes - Cardiovascular complications (myocardial infarction, stroke)

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters. - Assess nutritional status: monitor weight and appetite regularly. - Screen for thromboembolic risk: evaluate history of clotting disorders. - Monitor blood glucose: check fasting glucose in diabetic patients. - Check liver function: perform periodic hepatic enzyme tests. - Observe for adrenal suppression: watch for signs of cortisol deficiency. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Megaplex can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Anticoagulants: increased risk of bleeding. - CYP3A4 inhibitors: elevate megestrol concentrations, raising toxicity risk. - Hormonal contraceptives: reduced contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: may require dose adjustment of glucose‑lowering drugs. - Digoxin: possible increase in serum digoxin levels.